Literature DB >> 27416576

The 1st and the 2nd Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update.

Claudia Stefanutti1.   

Abstract

The clinical indications and guidelines for low-density lipoprotein (LDL)-apheresis set by the 1st Italian Consensus Conference held in Ostuni in 1990 and completed in 1992, but never published, are reported schematically. In 1994, within the Project "Prevention and control of the factors of the disease (FATMA)" by the Italian National Research Council, subproject 8 "Control of cardiovascular disease", a "Hearing on therapeutic apheresis: need for a target-oriented project" was organised. The meeting was the last scientific initiative on LDL-apheresis supported by public funds in Italy. After roughly two decades of use of LDL-apheresis, new guidelines were required based on the latest scientific evidence. In 2006, the Italian multicentre study on LDL-apheresis Working Group (IMSLDLa-WP), a scientific initiative at national level, was developed. It initially gathered together 19 Italian centres qualified for the application of lipid apheresis and LDL-apheresis (2007-2008), then 23 in 2010, located in the north, south, centre of Italy and in Sicily and Sardinia. The multicentre study aimed to validate the protocol for selecting patients and to create a network between the Italian centres. A secondary objective was the creation of a database of patients with familial hypercholesterolaemia and other severe forms of dyslipidaemia undergoing treatment with LDL-apheresis using the available techniques. Since LDL-apheresis has multidisciplinary treatment indications, the agreement on the new guidelines was reached through a panel of experts, of different medical and surgical specialties, with scientific and medical interest in the treatment indications, application and development of LDL-apheresis. The initiatives of the IMSLDLa-WP led to the 2nd Italian Consensus Conference on LDL-apheresis held in Rome in 2009. The previous and most recent guidelines are reported here synoptically.

Entities:  

Year:  2016        PMID: 27416576      PMCID: PMC5269426          DOI: 10.2450/2016.0272-15

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  16 in total

1.  High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography.

Authors:  Nico R Mollet; Filippo Cademartiri; Carlos A G van Mieghem; Giuseppe Runza; Eugène P McFadden; Timo Baks; Patrick W Serruys; Gabriel P Krestin; Pim J de Feyter
Journal:  Circulation       Date:  2005-10-03       Impact factor: 29.690

2.  National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary.

Authors:  Terry A Jacobson; Matthew K Ito; Kevin C Maki; Carl E Orringer; Harold E Bays; Peter H Jones; James M McKenney; Scott M Grundy; Edward A Gill; Robert A Wild; Don P Wilson; W Virgil Brown
Journal:  J Clin Lipidol       Date:  2014-07-15       Impact factor: 4.766

3.  The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Authors:  C Stefanutti; D J Blom; M R Averna; E A Meagher; H dT Theron; A D Marais; R A Hegele; C R Sirtori; P K Shah; D Gaudet; G B Vigna; B S Sachais; S Di Giacomo; A M E du Plessis; L T Bloedon; J Balser; D J Rader; M Cuchel
Journal:  Atherosclerosis       Date:  2015-03-14       Impact factor: 5.162

4.  Image quality in low-dose coronary computed tomography angiography with a new high-definition CT scanner.

Authors:  Egle Kazakauskaite; Lars Husmann; Julia Stehli; Tobias Fuchs; Michael Fiechter; Bernd Klaeser; Jelena R Ghadri; Catherine Gebhard; Oliver Gaemperli; Philipp A Kaufmann
Journal:  Int J Cardiovasc Imaging       Date:  2012-07-24       Impact factor: 2.357

5.  Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.

Authors:  Diederik F van Wijk; Barbara Sjouke; Amparo Figueroa; Hamed Emami; Fleur M van der Valk; Megan H MacNabb; Linda C Hemphill; Dominik M Schulte; Marion G Koopman; Mark E Lobatto; Hein J Verberne; Zahi A Fayad; John J P Kastelein; Willem J M Mulder; G Kees Hovingh; Ahmed Tawakol; Erik S G Stroes
Journal:  J Am Coll Cardiol       Date:  2014-10-07       Impact factor: 24.094

6.  Lipoprotein apheresis reduces circulating galectin-3 in humans.

Authors:  Isaac Eliaz; Elaine Weil; Julie-Ann Dutton; Audrey E McCalley; Barbie Nolte; Patrick M Moriarty
Journal:  J Clin Apher       Date:  2015-06-30       Impact factor: 2.821

7.  Angiographic and pathological studies on regression of coronary atherosclerosis of FH patients who received LDL-apheresis treatment.

Authors:  N Koga; Y Iwata; A Yamamoto
Journal:  Artif Organs       Date:  1992-04       Impact factor: 3.094

Review 8.  Applications of LDL-apheresis in nephrology.

Authors:  Shuzo Kobayashi
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

9.  Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

Authors:  Evan A Stein; Robert P Giugliano; Michael J Koren; Frederick J Raal; Eli M Roth; Robert Weiss; David Sullivan; Scott M Wasserman; Ransi Somaratne; Jae B Kim; Jingyuan Yang; Thomas Liu; Moetaz Albizem; Rob Scott; Marc S Sabatine
Journal:  Eur Heart J       Date:  2014-03-04       Impact factor: 29.983

Review 10.  Recommendations for the use of LDL apheresis.

Authors:  G R Thompson
Journal:  Atherosclerosis       Date:  2008-02-19       Impact factor: 5.162

View more
  3 in total

1.  The Italian Consensus Conferences on low density lipoprotein-cholesterol apheresis.

Authors:  Anja Vogt
Journal:  Blood Transfus       Date:  2016-07-07       Impact factor: 3.443

Review 2.  Recent Advances on Familial Hypercholesterolemia in Children and Adolescents.

Authors:  Francesca Mainieri; Veronica Maria Tagi; Francesco Chiarelli
Journal:  Biomedicines       Date:  2022-04-30

Review 3.  Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents.

Authors:  Hofit Cohen; Claudia Stefanutti
Journal:  Curr Atheroscler Rep       Date:  2021-05-08       Impact factor: 5.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.